Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity

Weight loss can reduce the increased cardiovascular risk associated with obesity. Pharmacotherapy is a recognized weight loss treatment option; however, cardiovascular safety issues with some previous weight loss drugs raise concerns for newly approved pharmacotherapies. Phentermine is approved for short-term obesity treatment in conjunction with lifestyle modifications, but is commonly used chronically. Topiramate, approved for treating epilepsy and preventing migraines, also induces weight loss. A single-dose combination of low-dose phentermine and topiramate extended-release was recently approved by the United States Food and Drug Administration as an adjunct to lifestyle intervention for the chronic treatment of overweight/obese adults. This review summarizes and evaluates the cardiovascular risk/benefit profile associated with phentermine and topiramate, individually and in combination. Cardiovascular data associated with long-term use of phentermine and topiramate extended-release indicate that this combination may be a safe and effective option for reducing weight in overweight/obese patients at low-to-intermediate cardiovascular risk.

[1]  F. Greenway,et al.  Addiction potential of phentermine prescribed during long-term treatment of obesity , 2014, International Journal of Obesity.

[2]  Jeroen J. Bax,et al.  2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.

[3]  S. Oparil,et al.  Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2). , 2013, The American journal of cardiology.

[4]  C. Torp‐Pedersen,et al.  Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial , 2012, Diabetes, obesity & metabolism.

[5]  Jens Jordan,et al.  Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. , 2012, Journal of hypertension.

[6]  D. Lau,et al.  The obesity epidemic and its impact on hypertension. , 2012, The Canadian journal of cardiology.

[7]  G. Derosa,et al.  Anti-obesity drugs: a review about their effects and their safety , 2012, Expert opinion on drug safety.

[8]  M. Myers,et al.  Role of GABA release from leptin receptor-expressing neurons in body weight regulation. , 2012, Endocrinology.

[9]  J. Kang,et al.  Anti-Obesity Drugs: A Review about Their Effects and Safety , 2012, Diabetes & metabolism journal.

[10]  C. Bouchard,et al.  Bariatric surgery and long-term cardiovascular events. , 2012, JAMA.

[11]  K. Gadde,et al.  Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP) , 2011, Obesity.

[12]  Abidemi K. Adeniji,et al.  Prevalence of adverse intraoperative events during obesity surgery and their sequelae. , 2011, Journal of the American College of Surgeons.

[13]  A. Powell.  Two-year sustained weight loss and metabolic benefits with controlled-release Phentermine/Topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study , 2012 .

[14]  F. Greenway,et al.  Blood Pressure and Heart Rate Effects, Weight Loss and Maintenance During Long‐Term Phentermine Pharmacotherapy for Obesity , 2011, Obesity.

[15]  R. Rothman,et al.  RE: Pulmonary Hypertension Associated with Use of Phentermine? , 2011, Yonsei medical journal.

[16]  T. Wadden,et al.  Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes , 2011, Diabetes Care.

[17]  B. Franklin,et al.  Recent Advances in Preventive Cardiology and Lifestyle Medicine Recent Advances in Preventive Cardiology and Lifestyle Medicine A Themed Series , 2011 .

[18]  K. Gadde,et al.  Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[19]  M. Davidson,et al.  WEIGHT LOSS AND CARDIOVASCULAR RISK REDUCTION OVER 2 YEARS WITH CONTROLLED-RELEASE PHENTERMINE-TOPIRAMATE , 2011 .

[20]  E. Ford,et al.  Proportion of the decline in cardiovascular mortality disease due to prevention versus treatment: public health versus clinical care. , 2011, Annual review of public health.

[21]  Bonnie Spring,et al.  The Potential of Virtual Reality Technologies to Improve Adherence to Weight Loss Behaviors , 2011, Journal of diabetes science and technology.

[22]  T. Pearson.  Recent Advances in Preventive Cardiology and Lifestyle Medicine Public Policy Approaches to the Prevention of Heart Disease and Stroke , 2011 .

[23]  J. Kang,et al.  Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse‐controlled release for obesity , 2010, Diabetes, obesity & metabolism.

[24]  H. Bays.  Phentermine, topiramate and their combination for the treatment of adiposopathy (‘sick fat’) and metabolic disease , 2010, Expert review of cardiovascular therapy.

[25]  Deepak L. Bhatt,et al.  Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial , 2010, The Lancet.

[26]  B. Joung,et al.  Pulmonary hypertension associated with use of phentermine. , 2010, Yonsei medical journal.

[27]  Susan T. Stewart,et al.  Forecasting the effects of obesity and smoking on U.S. life expectancy. , 2009, The New England journal of medicine.

[28]  F. Greenway,et al.  How Physician Obesity Specialists Use Drugs to Treat Obesity , 2009, Obesity.

[29]  R. Rothman,et al.  Serotonergic drugs and valvular heart disease , 2009, Expert opinion on drug safety.

[30]  Christine I. Turenius,et al.  GABAA receptors in the lateral hypothalamus as mediators of satiety and body weight regulation , 2009, Brain Research.

[31]  A. Halpern,et al.  A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects , 2004, International Journal of Obesity.

[32]  A. Park,et al.  CENTER FOR DRUG EVALUATION AND RESEARCH , 2009 .

[33]  A. Scheen.  The future of obesity: new drugs versus lifestyle interventions. , 2008, Expert opinion on investigational drugs.

[34]  Arya M. Sharma,et al.  Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. , 2007, European heart journal.

[35]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[36]  S. Rössner,et al.  Topiramate in the treatment of obese subjects with drug‐naive type 2 diabetes , 2007, Diabetes, obesity & metabolism.

[37]  P. Rahko,et al.  Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status , 2007, International Journal of Obesity.

[38]  S. Majumdar,et al.  Drug treatments for obesity: orlistat, sibutramine, and rimonabant , 2007, The Lancet.

[39]  M. Górska,et al.  Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study , 2007, International Journal of Obesity.

[40]  H. Kang,et al.  Effects on Weight Reduction and Safety of Short-Term Phentermine Administration in Korean Obese People , 2006, Yonsei medical journal.

[41]  R. Rothman,et al.  Amphetamine Analogs Increase Plasma Serotonin: Implications for Cardiac and Pulmonary Disease , 2006, Journal of Pharmacology and Experimental Therapeutics.

[42]  J. Killian,et al.  Secular Trends in Deaths From Cardiovascular Diseases: A 25-Year Community Study , 2006, Circulation.

[43]  C. Yosefy,et al.  Cusp tear in bicuspid aortic valve possibly caused by phentermine. , 2006, International Journal of Cardiology.

[44]  S. Tonstad,et al.  Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. , 2005, The American journal of cardiology.

[45]  H. Hauner,et al.  Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials , 2005, International Journal of Obesity.

[46]  T. Tomson,et al.  Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents , 2005, Epilepsy Research.

[47]  Arya M. Sharma,et al.  Paradoxical Effect of Sibutramine on Autonomic Cardiovascular Regulation , 2002, Clinical autonomic research : official journal of the Clinical Autonomic Research Society.

[48]  A. Astrup,et al.  Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. , 2004, Obesity research.

[49]  S. Silberstein,et al.  Topiramate in Migraine Prevention: Results of a Large Controlled Trial , 2004 .

[50]  A. Rissanen,et al.  A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects , 2004, International Journal of Obesity.

[51]  Arya M. Sharma,et al.  Selective Impairment in Sympathetic Vasomotor Control With Norepinephrine Transporter Inhibition , 2003, Circulation.

[52]  G. Bray,et al.  A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. , 2003, Obesity research.

[53]  T. Ryan,et al.  Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. , 2002, American heart journal.

[54]  P. Schraeder,et al.  Clinical Pharmacology: Drugs as a Benefit and/or Risk in Sudden Unexpected Death in Epilepsy? , 2002, Journal of clinical pharmacology.

[55]  Arya M. Sharma,et al.  Selective Norepinephrine Reuptake Inhibition as a Human Model of Orthostatic Intolerance , 2002, Circulation.

[56]  P. Tellier.  Fenfluramines, idiopathic pulmonary primary hypertension and cardiac valve disorders: facts and artifacts. , 2001, Annales de medecine interne.

[57]  L. Sjöström,et al.  The Swedish Obese Subjects (SOS) study—rationale and results , 2001, International Journal of Obesity.

[58]  K. Rice,et al.  Amphetamine‐type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin , 2001, Synapse.

[59]  Y. Deshaies,et al.  Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. , 2000, Obesity research.

[60]  M. Baican,et al.  Hypotensive effect of calcium channel blockers is parallel with carbonic anhydrase I inhibition , 2000, Clinical pharmacology and therapeutics.

[61]  S. Schneeweiss,et al.  Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. , 2000, Chest.

[62]  M. F. Sugrue.  Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors , 2000, Progress in Retinal and Eye Research.

[63]  R. Rothman,et al.  Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. , 1999, Circulation.

[64]  W. White,et al.  Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension. , 1998, American journal of hypertension.

[65]  M. Baican,et al.  Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. , 1999, Drugs under experimental and clinical research.

[66]  L. Weinrauch,et al.  A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. , 1998, The New England journal of medicine.

[67]  Schembre Db,et al.  Appetite-suppressant drugs and primary pulmonary hypertension. , 1997 .

[68]  A. Fishman.  Appetite-suppressant drugs and primary pulmonary hypertension. , 1997, The New England journal of medicine.

[69]  M. Worsham,et al.  Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. , 1997, MMWR. Morbidity and mortality weekly report.

[70]  F. Greenway.  Surgery for obesity. , 1996, Endocrinology and metabolism clinics of North America.

[71]  S. Shorvon.  Safety of Topiramate: Adverse Events and Relationships to Dosing , 1996, Epilepsia.

[72]  M. Esler,et al.  Central sympathoinhibition and peripheral neuronal uptake blockade after desipramine in rabbits. , 1991, The American journal of physiology.

[73]  R. Westerman,et al.  Effects of desipramine on sympathetic nerve firing and norepinephrine spillover to plasma in humans. , 1991, The American journal of physiology.

[74]  R B D'Agostino,et al.  Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. , 1990, The New England journal of medicine.

[75]  J. Vallé-Jones,et al.  A comparative study of phentermine and diethylpropion in the treatment of obese patients in general practice. , 1983, Pharmatherapeutica.

[76]  DifcoTM HycheckTM,et al.  The package insert. , 1969, JAMA.

[77]  L. J. Duncan,et al.  Comparison of continuous and intermittent anorectic therapy in obesity. , 1968, British medical journal.